ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Renal Cell Carcinoma

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Renal Cell Carcinoma
ZOMETA reduces SREs

Page

1 2

ZOMETA^® can delay time to first pathologic fracture with advanced
renal cell carcinoma

Time to first pathologic fracture⁵

$Time to first pathologic fracture$

ZOMETA^® significantly extended median time to first pathologic fracture vs placebo (median not reached vs 168 days, P=.003)⁵

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® can delay time to first pathologic fracture with advanced renal cell carcinoma

ZOMETA® significantly extended median time to first pathologic fracture vs placebo (median not reached vs 168 days, P=.003)5

ZOMETA^® can delay time to first pathologic fracture with advanced
renal cell carcinoma

ZOMETA^® significantly extended median time to first pathologic fracture vs placebo (median not reached vs 168 days, P=.003)⁵